Skip to main content
×
×
Home

Treatment resistant schizophrenia – review and a call to action

  • J. Lally (a1) (a2) (a3) (a4) and F. Gaughran (a1) (a5)
Abstract

Recovery rates in schizophrenia remain suboptimal with up to one-third resistant to standard treatments, a population prevalence of 0.2%. Clozapine is the only evidenced-based treatment for treatment resistant schizophrenia (TRS), yet there are significant delays in its use or it may not be trialled, potentially impacting the chance of recovery. Better outcomes with earlier use of clozapine may be possible. There is emerging evidence that early treatment resistance is not uncommon from the earliest stages of psychosis. In this review, we provide an update on TRS, its epidemiology and its management, with a specific focus on the optimal use and timing of clozapine and augmentation strategies for the one-third of patients who do not respond to clozapine.

Copyright
Corresponding author
*Address for correspondence: Dr John Lally, PO63, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, De Crespigny Park, London SE5 8AF, UK. (Email: john.lally@kcl.ac.uk)
References
Hide All
Agid, O, Arenovich, T, Sajeev, G, Zipursky, RB, Kapur, S, Foussias, G, Remington, G (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry 72, 14391444.
Agid, O, Kapur, S, Arenovich, T, Zipursky, RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 12281235.
Antonio Pinto, SLP, Rosa, M, Domenico, G, Luigi, D (1999). Rehab rounds: cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatric Services 50, 901904.
Bachmann, CJ, Aagaard, L, Bernardo, M, Brandt, L, Cartabia, M, Clavenna, A, Coma Fuste, A, Furu, K, Garuoliene, K, Hoffmann, F, Hollingworth, S, Huybrechts, KF, Kalverdijk, LJ, Kawakami, K, Kieler, H, Kinoshita, T, Lopez, SC, Machado-Alba, JE, Machado-Duque, ME, Mahesri, M, Nishtala, PS, Piovani, D, Reutfors, J, Saastamoinen, LK, Sato, I, Schuiling-Veninga, CCM, Shyu, YC, Siskind, D, Skurtveit, S, Verdoux, H, Wang, LJ, Zara Yahni, C, Zoega, H, Taylor, D (2017). International trends in clozapine use: a study in 17 countries. Acta Psychiatrica Scandinavica 136, 3751.
Barnes, TR, Leeson, VC, Paton, C, Marston, L, Davies, L, Whittaker, W, Osborn, D, Kumar, R, Keown, P, Zafar, R, Iqbal, K, Singh, V, Fridrich, P, Fitzgerald, Z, Bagalkote, H, Haddad, PM, Husni, M, Amos, T (2017). Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technology Assessment 21, 156.
Barretto, EM, Kayo, M, Avrichir, BS, Sa, AR, Camargo, M, Napolitano, IC, Nery, FG, Pinto, JA Jr., Bannwart, S, Scemes, S, Di Sarno, E, Elkis, H (2009). A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. Journal of Nervous and Mental Disease 197, 865868.
Brunette, MF, Drake, RE, Xie, H, McHugo, GJ, Green, AI (2006). Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin 32, 637643.
Burns, A, Erickson, H, Brenner, C (2014). Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatric Services 65, 874880.
Carbon, M, Correll, CU (2014). Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues in Clinical Neuroscience 16, 505524.
Chakos, M, Lieberman, J, Hoffman, E, Bradford, D, Sheitman, B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518526.
Chang, JS, Ahn, YM, Park, HJ, Lee, KY, Kim, SH, Kang, UG, Kim, YS (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 720731.
Conley, RR, Kelly, DL, Richardson, CM, Tamminga, CA, Carpenter, WT Jr. (2003). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. Journal of Clinical Psychopharmacology 23, 668671.
Correll, CU, Rubio, JM, Inczedy-Farkas, G, Birnbaum, ML, Kane, JM, Leucht, S (2017). Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74, 675684.
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443457.
Davis, MC, Fuller, MA, Strauss, ME, Konicki, PE, Jaskiw, GE (2014). Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatrica Scandinavica 130, 3039.
de Boer, J, Prikken, M, Lei, WU, Begemann, M, Sommer, I (2018). The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis. npj Schizophrenia 4, 1.
Demjaha, A, Egerton, A, Murray, RM, Kapur, S, Howes, OD, Stone, JM, McGuire, PK (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biological Psychiatry 75, e11e13.
Demjaha, A, Lappin, JM, Stahl, D, Patel, MX, MacCabe, JH, Howes, OD, Heslin, M, Reininghaus, UA, Donoghue, K, Lomas, B, Charalambides, M, Onyejiaka, A, Fearon, P, Jones, P, Doody, G, Morgan, C, Dazzan, P, Murray, RM (2017). Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychological Medicine 47, 19811989.
Demjaha, A, Murray, RM, McGuire, PK, Kapur, S, Howes, OD (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 169, 12031210.
Downs, J, Zinkler, M (2007). Clozapine: national review of postcode prescribing. The Psychiatrist 31, 384387.
Doyle, R, Behan, C, O’Keeffe, D, Masterson, S, Kinsella, A, Kelly, A, Sheridan, A, Keating, D, Hynes, C, Madigan, K, Lawlor, E, Clarke, M (2017). Clozapine use in a cohort of first-episode psychosis. Journal of Clinical Psychopharmacol 37, 512517.
Elkis, H, Buckley, PF (2016). Treatment-resistant schizophrenia. Psychiatric Clinics of North America 39, 239265.
Fernandez-Egea, E, Worbe, Y, Bernardo, M, Robbins, TW (2018). Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. Psychological Medicine 19, 18.
Frogley, C, Taylor, D, Dickens, G, Picchioni, M (2012). A systematic review of the evidence of clozapine’s anti-aggressive effects. International Clinical Psychopharmacology 15, 13511371.
Galling, B, Roldan, A, Hagi, K, Rietschel, L, Walyzada, F, Zheng, W, Cao, XL, Xiang, YT, Zink, M, Kane, JM, Nielsen, J, Leucht, S, Correll, CU (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16, 7789.
Galling, B, Vernon, JA, Pagsberg, AK, Wadhwa, A, Grudnikoff, E, Seidman, AJ, Tsoy-Podosenin, M, Poyurovsky, M, Kane, JM, Correll, CU (2018). Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica 137, 187205.
Gregory, A, Mallikarjun, P, Upthegrove, R (2017). Treatment of depression in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 211, 198204.
Hayes, RD, Downs, J, Chang, CK, Jackson, RG, Shetty, H, Broadbent, M, Hotopf, M, Stewart, R (2015). The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophrenia Bulletin 41, 644655.
Horsdal, HT, Wimberley, T, Kohler-Forsberg, O, Baandrup, L, Gasse, C (2017). Association between global functioning at first schizophrenia diagnosis and treatment resistance. Early Intervention Psychiatry. Published online 8 December 2017. doi:10.1111/eip.12522.
Howes, OD, McCutcheon, R, Agid, O, de Bartolomeis, A, van Beveren, NJ, Birnbaum, ML, Bloomfield, MA, Bressan, RA, Buchanan, RW, Carpenter, WT, Castle, DJ, Citrome, L, Daskalakis, ZJ, Davidson, M, Drake, RJ, Dursun, S, Ebdrup, BH, Elkis, H, Falkai, P, Fleischacker, WW, Gadelha, A, Gaughran, F, Glenthoj, BY, Graff-Guerrero, A, Hallak, JE, Honer, WG, Kennedy, J, Kinon, BJ, Lawrie, SM, Lee, J, Leweke, FM, MacCabe, JH, McNabb, CB, Meltzer, H, Moller, HJ, Nakajima, S, Pantelis, C, Reis Marques, T, Remington, G, Rossell, SL, Russell, BR, Siu, CO, Suzuki, T, Sommer, IE, Taylor, D, Thomas, N, Ucok, A, Umbricht, D, Walters, JT, Kane, J, Correll, CU (2017). Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry 174, 216229.
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry 201, 481485.
Itil, TM, Keskiner, A, Fink, M (1966). Therapeutic studies in “therapy resistant” schizophrenic patients. Comprehensive Psychiatry 7, 488493.
Iwata, Y, Nakajima, S, Plitman, E, Caravaggio, F, Kim, J, Shah, P, Mar, W, Chavez, S, De Luca, V, Mimura, M, Remington, G, Gerretsen, P, Graff-Guerrero, A (2018). Glutamatergic neurometabolite levels in patients with ultra treatment-resistant schizophrenia: a cross-sectional 3T Proton MRS study. Biological Psychiatry. Published online 26 September 2018. doi:10.1016/j.biopsych.2018.09.009.
Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, Veijola, J, Miettunen, J (2013). A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin 39, 12961306.
Jauhar, S, McKenna, PJ, Radua, J, Fung, E, Salvador, R, Laws, KR (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry 204, 2029.
Kahn, RS, Winter van Rossum, I, Leucht, S, McGuire, P, Lewis, SW, Leboyer, M, Arango, C, Dazzan, P, Drake, R, Heres, S, Díaz-Caneja, CM, Rujescu, D, Weiser, M, Galderisi, S, Glenthøj, B, Eijkemans, MJC, Fleischhacker, WW, Kapur, S, Sommer, IE, Kahn, RS, Sommer, IE, Winter-van Rossum, I, Somers, M, Ywema, PC, Kapur, S, McGuire, P, Leboyer, M, Meyer-Lindenberg, A, Lewis, SW, Leucht, S, Arango, C, Fleischhacker, WW, Meijering, AL, Petter, J, Van de Brug, R, Schotsman, J, Zwerver, J, Peuskens, J, De Hert, M, Thys, E, Hranov, LG, Hranov, V, Libiger, J, Köhler, R, Mohr, P, Glenthoj, B, Broberg, B, Düring, S, Baandrup, L, Jamain, S, Heres, S, Rujescu, D, Giegling, I, Weiser, M, Bar Heim, M, Davidson, M, Galderisi, S, Bucci, P, Mucci, A, Rybakowski, J, Remlinger-Molenda, A, Gonen, I, Radu, P, Díaz-Marsá, M, Rodriguez, A, Palomo, T, Rodriguez-Jimenez, R, García-Portilla, P, Bernardo, M, Bobes, J, Vilares Oliveira, C, Berger, G, Wildt, C, Dazzan, P, Perez-Iglesias, R, Drake, R, Gregory, S, Wilson, D, Díaz-Caneja, CM, Eijkemans, MJC (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The Lancet Psychiatry. Published online 13 August 2018. doi: 10.1016/S2215-0366(18)30252-9.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789796.
Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I, Hornberger, JC (2014). The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. International Clinical Psychopharmacology 29, 6376.
Kirwan, P, O’Connor, L, Sharma, K, McDonald, C (2017). The impact of switching to clozapine on psychiatric hospital admissions: a mirror-image study. Irish Journal of Psychological Medicine 15.
Kohler-Forsberg, O, Horsdal, HT, Legge, SE, MacCabe, JH, Gasse, C (2017). Predictors of nonhospitalization and functional response in clozapine treatment: a nationwide, population-based cohort study. Journal of Clinical Psychopharmacology 37, 148154.
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63, 622629.
Kulkarni, J, Gavrilidis, E, Gwini, SM, Worsley, R, Grigg, J, Warren, A, Gurvich, C, Gilbert, H, Berk, M, Davis, SR (2016). Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry 73, 947954.
Kulkarni, J, Gavrilidis, E, Wang, W, Worsley, R, Fitzgerald, PB, Gurvich, C, Van Rheenen, T, Berk, M, Burger, H (2015). Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Molecular Psychiatry 20, 695702.
Kumra, S, Kranzler, H, Gerbino-Rosen, G, Kester, HM, DeThomas, C, Kafantaris, V, Correll, CU, Kane, JM (2008). Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry 63, 524529.
Lally, J, Ajnakina, O, Di Forti, M, Trotta, A, Demjaha, A, Kolliakou, A, Mondelli, V, Reis Marques, T, Pariante, C, Dazzan, P, Shergil, SS, Howes, OD, David, AS, MacCabe, JH, Gaughran, F, Murray, RM (2016a). Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine 46, 32313240.
Lally, J, Ajnakina, O, Stubbs, B, Cullinane, M, Murphy, KC, Gaughran, F, Murray, RM (2017a). Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. British Journal of Psychiatry 211, 350358.
Lally, J, Al Kalbani, H, Krivoy, A, Murphy, KC, Gaughran, F, MacCabe, JH (2018). Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. Journal of Clinical Psychopharmacology 38, 520527.
Lally, J, Gaughran, F, Timms, P, Curran, SR (2016b). Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics and Personalized Medicine 9, 117129.
Lally, J, Malik, S, Krivoy, A, Whiskey, E, Taylor, DM, Gaughran, FP, Flanagan, RJ, Mijovic, A, MacCabe, JH (2017b). The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. Journal of Clinical Psychopharmacology 37, 600604.
Lally, J, Tully, J, Robertson, D, Stubbs, B, Gaughran, F, MacCabe, JH (2016c). Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 171, 215224.
Leucht, S, Helfer, B, Dold, M, Kissling, W, McGrath, JJ (2015a). Lithium for schizophrenia. Cochrane Database of Systematic Reviews, Cd003834.
Leucht, S, Samara, M, Heres, S, Davis, JM (2016). Dose equivalents for antipsychotic drugs: the DDD method. Schizophrenia Bulletin 42 (Suppl 1): S90S94.
Leucht, S, Samara, M, Heres, S, Patel, MX, Furukawa, T, Cipriani, A, Geddes, J, Davis, JM (2015b). Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophrenia Bulletin 41, 13971402.
Lokshin, P, Lerner, V, Miodownik, C, Dobrusin, M, Belmaker, RH (1999). Parenteral clozapine: five years of experience. Journal of Clinical Psychopharmacology 19, 479480.
Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU (2012). When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophrenia Research 134, 180186.
McCutcheon, R, Beck, K, Bloomfield, MA, Marques, TR, Rogdaki, M, Howes, OD (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology 29, 892897.
McCutcheon, R, Beck, K, D’Ambrosio, E, Donocik, J, Gobjila, C, Jauhar, S, Kaar, S, Pillinger, T, Reis Marques, T, Rogdaki, M, Howes, OD (2018). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatrica Scandinavica 137, 3946.
McGrath, J, Saha, S, Chant, D, Welham, J (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 30, 6776.
Meltzer, HY (1992). Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 18, 515542.
Meltzer, HY, Alphs, L, Green, AI, Altamura, AC, Anand, R, Bertoldi, A, Bourgeois, M, Chouinard, G, Islam, MZ, Kane, J, Krishnan, R, Lindenmayer, JP, Potkin, S (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 8291.
Meltzer, HY, Bobo, WV, Roy, A, Jayathilake, K, Chen, Y, Ertugrul, A, Anil Yagcioglu, AE, Small, JG (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 69, 274285.
Melzer-Ribeiro, DL, Rigonatti, SP, Kayo, M, Avrichir, BS, Ribeiro, RB, Santos, BD, Fortes, M, Elkis, H (2017). Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT sham controlled trial. Archives of Clinical Psychiatry (São Paulo) 44, 4550.
Moreno-Kustner, B, Martin, C, Pastor, L (2018). Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 13, e0195687.
Morrison, AP, Pyle, M, Gumley, A, Schwannauer, M, Turkington, D, MacLennan, G, Norrie, J, Hudson, J, Bowe, SE, French, P, Byrne, R, Syrett, S, Dudley, R, McLeod, HJ, Griffiths, H, Barnes, TRE, Davies, L, Kingdon, D, Aydinlar, S, Courtley, J, Douglas-Bailey, M, Graves, E, Holden, N, Hutton, J, Hutton, P, Irving, S, Jackson, C, Lebert, T, Mander, H, McCartney, L, Munro-Clark, T, Murphy, EK, Spanswick, M, Steele, A, Tip, L, Tully, S (2018). Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. The Lancet Psychiatry 5, 633643.
Mouchlianitis, E, Bloomfield, MA, Law, V, Beck, K, Selvaraj, S, Rasquinha, N, Waldman, A, Turkheimer, FE, Egerton, A, Stone, J, Howes, OD (2016). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophrenia Bulletin 42, 744752.
Muscatello, MR, Bruno, A, Pandolfo, G, Mico, U, Scimeca, G, Di Nardo, F, Santoro, V, Spina, E, Zoccali, RA (2011). Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophrenia Research 127, 9399.
Mustafa, FA, Burke, JG, Abukmeil, SS, Scanlon, JJ, Cox, M (2015). “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry 48, 1114.
NICE (2014). Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178). Royal College of Psychiatrists: London.
Nielsen, J, Correll, CU, Manu, P, Kane, JM (2013). Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? Journal of Clinical Psychiatry 74, 603613.
Nielsen, J, Dahm, M, Lublin, H, Taylor, D (2010). Psychiatrists’ attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 24, 965971.
Nielsen, J, Nielsen, RE, Correll, CU (2012). Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Journal of Clinical Psychopharmacology 32, 678683.
Nielsen, J, Young, C, Ifteni, P, Kishimoto, T, Xiang, YT, Schulte, PF, Correll, CU, Taylor, D (2016). Worldwide differences in regulations of clozapine use. CNS Drugs 30, 149161.
Pai, NB, Vella, SC (2012). Reason for clozapine cessation. Acta Psychiatrica Scandinavica 125, 3944.
Petrides, G, Malur, C, Braga, RJ, Bailine, SH, Schooler, NR, Malhotra, AK, Kane, JM, Sanghani, S, Goldberg, TE, John, M, Mendelowitz, A (2015). Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry 172, 5258.
Pharoah, F, Mari, J, Rathbone, J, Wong, W (2010). Family intervention for schizophrenia. Cochrane Database of Systematic Reviews, Cd000088.
Remington, G, Agid, O, Foussias, G, Ferguson, L, McDonald, K, Powell, V (2013). Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 225, 505518.
Ringback Weitoft, G, Berglund, M, Lindstrom, EA, Nilsson, M, Salmi, P, Rosen, M (2014). Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study. Pharmacoepidemiology and Drug Safety 23, 290298.
Samanaite, R, Gillespie, A, Sendt, KV, McQueen, G, MacCabe, JH, Egerton, A (2018). Biological predictors of clozapine response: a systematic review. Frontiers in Psychiatry 9, 327.
Schirmbeck, F, Zink, M (2012). Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Current Neuropharmacology 10, 8895.
Schulte, P (2003). What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clinical Pharmacokinetics 42, 607618.
Schulte, PFJ, Stienen, JJ, Bogers, J, Cohen, D, van Dijk, D, Lionarons, WH, Sanders, SS, Heck, AH (2007). Compulsory treatment with clozapine: a retrospective long-term cohort study. International Journal of Law and Psychiatry 30, 539545.
Shiloh, R, Zemishlany, Z, Aizenberg, D, Radwan, M, Schwartz, B, Dorfman-Etrog, P, Modai, I, Khaikin, M, Weizman, A (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry 171, 569573.
Siskind, D, Siskind, V, Kisely, S (2017). Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Canadian Journal of Psychiatry 62, 772777.
Siskind, DJ, Lee, M, Ravindran, A, Zhang, Q, Ma, E, Motamarri, B, Kisely, S (2018). Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry 52, 751767.
Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S (2012). Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38, 10031011.
Srisurapanont, M, Suttajit, S, Maneeton, N, Maneeton, B (2015). Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Journal of Psychiatric Research 62, 3847.
Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatric Services 65, 186192.
Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M (2016). Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. American Journal of Psychiatry 173, 166173.
Swets, M, Dekker, J, van Emmerik-van Oortmerssen, K, Smid, GE, Smit, F, de Haan, L, Schoevers, RA (2014). The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophrenia Research 152, 458468.
Taipale, H, Mehtala, J, Tanskanen, A, Tiihonen, J (2017). Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia – a nationwide study with 20-year follow-up. Schizophrenia Bulletin 44, 13811387.
Taylor, DM, Barnes, TRE, Young, AH (2018). The Maudsley Prescribing Guidelines in Psychiatry. Wiley: UK.
Taylor, DM, Smith, L, Gee, SH, Nielsen, J (2012). Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatrica Scandinavica 125, 1524.
Taylor, DM, Young, C, Paton, C (2003). Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64, 3034.
Tharyan, P, Adams, CE (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews CD000076.
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX, Korhonen, P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168, 603609.
Tiihonen, J, Lonnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, Haukka, J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620627.
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, Mehtala, J, Hoti, F, Jedenius, E, Enkusson, D, Leval, A, Sermon, J, Tanskanen, A, Taipale, H (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 74, 686693.
Tollefson, GD, Birkett, MA, Kiesler, GM, Wood, AJ (2001). Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry 49, 5263.
Ucok, A, Cikrikcili, U, Karabulut, S, Salaj, A, Ozturk, M, Tabak, O, Durak, R (2015). Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International Clinical Psychopharmacology 30, 290295.
Verdoux, H, Quiles, C, Bachmann, CJ, Siskind, D (2018). Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophrenia Research. Published online 4 June 2018. doi:10.1016/j.schres.2018.05.046
Vermeulen, JM, van Rooijen, G, van de Kerkhof, MPJ, Sutterland, AL, Correll, CU, de Haan, L (2018). Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 Years. Schizophr Bull. Published online 25 April 2018. doi:10.1093/schbul/sby052.
Weiser, M, Levi, L, Burshtein, S, Hagin, M, Matei, VP, Podea, D, Micluţia, I, Tiugan, A, Pacala, B, Grecu, IG, Noy, A, Zamora, D, Davis, JM (2017). Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. Journal of Clinical Psychiatry 78, e758e765.
Wheeler, AJ (2008). Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Annals of Pharmacotherapy 42, 852860.
Wimberley, T, MacCabe, JH, Laursen, TM, Sorensen, HJ, Astrup, A, Horsdal, HT, Gasse, C, Stovring, H (2017). Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. American Journal of Psychiatry 174, 990998.
Wimberley, T, Støvring, H, Sørensen, HJ, Horsdal, HT, MacCabe, JH, Gasse, C (2016). Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. The Lancet Psychiatry 3, 358366.
Yoshimura, B, Yada, Y, So, R, Takaki, M, Yamada, N (2017). The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychological Medicine 250, 6570.
Zheng, W, Xiang, YT, Yang, XH, Xiang, YQ, de Leon, J (2017). Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 78, e498e505.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Irish Journal of Psychological Medicine
  • ISSN: 0790-9667
  • EISSN: 2051-6967
  • URL: /core/journals/irish-journal-of-psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed